Gottlieb Looks Like Good Fit At FDA Helm To Supplement Industry
This article was originally published in The Rose Sheet
Executive Summary
Scott Gottlieb’s two stints at FDA and his support for limiting regulation that impedes innovation bode well for a supplement industry anxious for guidance on NDI notifications that aligns more with its expectation for less burdensome requirements than those the agency has stated.
You may also be interested in...
US FDA Commissioner Confirmation: Gottlieb To Get Questions On Approval Standards, Ties To Industry
Top Senate committee Democrat Patty Murray tweeted concerns about Gottlieb's positions on 'gold standard' of FDA approval; Public Citizen's Michael Carome ultimately thinks Gottlieb will be approved.
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”